New hope for Hard-to-Treat cancers: experimental drug DB-1311 enters human trials

NCT ID NCT05914116

Disease control Sponsor: DualityBio Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called DB-1311/BNT324 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 862 adults will take part in this early-phase trial across multiple centers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 862 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2023

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female adults (defined as ≥ 18 years of age or acceptable age according to local regulations at the time of voluntarily signing of informed consent). 2. Histologically or cytologically confirmed unresectable advanced/metastatic solid tumor that has relapsed or progressed on or after standard systemic treatments, or is intolerable with standard treatment; or for which no standard treatment is available. 3. At least one measurable lesion as assessed by the investigator according to response evaluation criteria in solid tumors (RECIST) version 1.1 criteria (measurable disease as defined by RANO 2.0 criteria for GBM subjects). Castrate-resistant prostate cancer (CRPC) subjects with bone only disease may be eligible on a case-by- case basis after discussion with the Medical Monitor. 4. Has a life expectancy of ≥ 3 months. 5. Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1. 6. Has LVEF ≥ 50% by either echocardiography (ECHO) or multiple-gated acquisition (MUGA) within 28 days before enrollment. 7. Has adequate organ function within 7 days prior to Day 1 of Cycle 1 8. Has adequate treatment washout period prior to Day 1 of Cycle 1 9. Is willing to provide pre-existing resected tumor samples or undergo fresh tumor biopsy for the measurement of B7-H3 level and other biomarkers if no contraindication. Note: there is no minimum B7-H3 expression level mandatory for entry into the study. 10. Is capable of comprehending study procedures and risks outlined in the informed consent and able to provide written consent and agree to comply with the requirements of the study and the schedule of assessments. 11. Male and female subjects of reproductive/childbearing potential must agree to use adequate contraceptive methods (e.g., double barrier or intrauterine contraceptive) during the study and for at least 4 months and 7 months after the last dose of study drug, respectively. 12. Male subjects must not freeze or donate sperm starting at screening and throughout the study period, and at least 4 months after the final study drug administration. 13. Female subjects must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and for at least 7 months after the final study drug administration. 14. SCLC subjects (Phase 2a Cohort 1 ONLY): * Pathologically documented locally advanced, or metastatic SCLC not amenable to curative surgery or radiation. * Prior therapy with at least one platinum-based line as systemic therapy for extensive stage disease with at least two cycles of therapy (except in the case of early objective PD). * Prior treatment regimens with irinotecan, topotecan or any other TOP I inhibitor including investigational TOP I inhibitors are not allowed. 15. NSCLC subjects (Phase 2a Cohort 2 ONLY): * Pathologically documented locally advanced, or metastatic NSCLC and is not amenable to curative surgery or radiation. * Has received prior treatment with platinum-based chemotherapy regimen and/or anti-PD-1/PD-L1 antibody-based regimen in the advanced/unresectable, or metastatic setting unless unable or unwilling. Subjects with NSCLC known to harbor a genomic alteration(s) other than EGFR mutation(s) (e.g., ALK rearrangement, ROS1 rearrangement, KRAS G12C mutation, BRAF V600E mutation, NTRK1/2/3 Gene fusion, MET Exon 14 skipping, RET rearrangement etc.) for which treatment is available must have also received prior treatment with at least 1 genotype-directed therapy. 16. ESCC subjects (Phase 2a Cohort 3 ONLY): * Pathologically documented locally advanced, or metastatic ESCC and is not amenable to curative surgery or radiation. * Having received at least one prior therapy for unresectable disease. Patients with recurrence within 6 months of completion of neoadjuvant or adjuvant therapy will be considered as having received one prior therapy for unresectable disease. 17. CRPC subjects (Phase 2a Cohort 4 ONLY): • Pathologically documented metastatic adenocarcinoma of the prostate cancer. * Progressive metastatic CRPC as defined: 1) castrate levels of serum testosterone \< 50 ng/dL AND 2) progressive disease as defined by PCWG3 criteria. * Having received prior docetaxel (before or after an AR-targeted therapy). Docetaxel rechallenge was allowed. * Having received prior novel hormone therapy. 18. Melanoma subjects (Phase 2a Cohort 5 ONLY) • Histologically or cytologically confirmed diagnosis of unresectable Stage III or metastatic melanoma not amenable to local therapy, must have had either: \> Previously treated with a PD-1 or PD-L1 inhibitor. \> If subjects with BRAF gene mutant melanoma, must have had a prior treatment regimen that included vemurafenib, dabrafenib, or another BRAF gene and/or mitogen-activated protein kinase (MEK) protein inhibitor. 19. HCC subjects (Phase 2a Cohort 6 ONLY) * Histological/cytological confirmed diagnosis of HCC or clinically confirmed diagnosis of HCC as per American Association for the Study of Liver Diseases (AASLD) criteria (fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC are not eligible), and: * Has received 1 or 2 prior systemic therapy regimens for recurrent or metastatic disease; * Has experienced disease progression during or after treatment with an anti-PD-1/L1 agent administered either as monotherapy or in combination. Note: Subjects basically should receive prior standard therapy. • However, if the investigator judges the therapy is not appropriate for the subject, the prior standard therapy is not necessarily mandated for the eligibility. • Has a Child-Pugh class A liver score within 7 days of first dose of study drug. 20. Cervical cancer subjects (Phase 2a Cohort 7 ONLY) • Has recurrent or metastatic cervical cancer with squamous cell, adenocarcinoma, or adenosquamous histology, and: • Has experienced disease progression during or after treatment with a standard of care systemic chemotherapy doublet, or platinum-based therapy (if eligible), defined as either: d. paclitaxel + cisplatin + bevacizumab + anti-PD-(L)1 agent, or e. paclitaxel + carboplatin + bevacizumab + anti-PD-(L)1 agent, or f. paclitaxel + topotecan + bevacizumab + anti-PD-(L)1 agent Note: In cases where bevacizumab and/or anti-PD-(L)1 agent is not a standard of care therapy or the subject was ineligible for such treatment according to local standards, prior treatment with bevacizumab and/or anti-PD-(L)1 agent is not required. • Has received 1 or 2 prior systemic therapy regimens for recurrent or metastatic cervical cancer. Chemotherapy administered in the adjuvant or neoadjuvant setting, or in combination with radiation therapy, should not be counted as a systemic therapy regimen. Single agent therapy with an anti-PD(L)1 agent for recurrent or metastatic cervical cancer should be counted. 21. Subjects with other solid tumors (Phase 2a Cohort 8 ONLY) • Histologically or cytologically confirmed solid tumors. • Progressed or relapsed after at least one prior standard therapeutic regimen (Patients who have not received all approved or standard treatments for their cancer must be informed that these alternatives to receiving DB-1311/BNT324 are available prior to consenting to participate in this trial). 22. HNSCC subjects (Phase 2a Cohort 9 and Cohort 13) • Histologically or cytologically confirmed refractory/metastatic (R/M) HNSCC (not including NPC) that is considered incurable by local therapies. • Progressed on or after prior standard therapeutic regimen. 23. Subjects with rare tumors (Phase 2a Cohort 10 ONLY) Histologically or cytologically confirmed rare tumor types. Progressed or relapsed after at least one prior standard therapeutic regimen (Patients who have not received all approved or standard treatments for their cancer must be informed that these alternatives to receiving DB-1311/BNT324 are available prior to consenting to participate in this trial). 24. Post lutetium-177 CRPC subjects (Phase 2a Cohort 11 ONLY): Pathologically documented metastatic adenocarcinoma of the prostate cancer. Progressive metastatic CRPC as defined: 1) castrate levels of serum testosterone \< 50 ng/dL AND 2) progressive disease as defined by PCWG3 criteria. 25. Taxane-naive CRPC subjects (Phase 2a Cohort 12, 16, 17 ONLY) * Pathologically documented metastatic adenocarcinoma of the prostate cancer. Progressive metastatic CRPC as defined: 1) castrate levels of serum testosterone \< 50 ng/dL AND 2) progressive disease as defined by PCWG3 criteria. 26, PROC subjects (Phase 2a Cohort 14 ONLY) * Subjects must have a confirmed diagnosis of OC, primary peritoneal cancer, or fallopian tube cancer, all of which with high-grade serous or endometrioid histology.. * Subjects must have platinum-resistant disease: * Received at least 1 but ≤ 3 lines of prior systemic anticancer therapy and have radiographic progressed on or after their most recent line of therapy. 27\. CSPC with suboptimal PSA response (Phase 2a Cohort 18 ONLY) * Pathologically documented adenocarcinoma of the prostate cancer. * Having advanced/unresectable, or metastatic disease and confirmed by imaging (e.g., CT and/or bone scan). * Having received ADT and enzalutamide or abiraterone for ≥4 months, with suboptimal PSA response. 28\. Additional inclusion criteria for DDI cohort: has a study treatment expectancy of \>= 2.5 months. Able to withhold CYP3A/P-gp/OATP1B inhibitors or substrates or CYP3A inducers as concomitant treatments for certain period. Exclusion Criteria: Unless otherwise specified, the exclusion criteria are common to both Phase 1 and Phase 2a. Subjects who meet any of the following criteria will be excluded from the study: 1. Prior treatment with B7-H3 targeted therapy. 2. Prior treatment with antibody drug conjugate with topoisomerase inhibitor (e.g., trastuzumab deruxtecan). 3. Has a medical history of symptomatic congestive heart failure (CHF) (New York Heart Association \[NYHA\] classes II-IV) or serious cardiac arrhythmia requiring treatment. 4. Has a medical history of myocardial infarction or unstable angina within 6 months before enrollment. 5. Has an average of Fredericia's formula-QT corrected interval (QTcF) prolongation to \> 470 millisecond (ms) in males and females based on a 12-lead electrocardiogram (ECG) in triplicate. 6. Use of concomitant medications known to prolong the QT interval. If the use is deemed necessary, they should be administered with caution and closely monitoring the QT interval, after discussed with the Sponsor. 7. Has a medical history of interstitial lung diseases (e.g., non-infectious interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or current interstitial lung diseases or who are suspected to have these diseases by imaging at screening. 8. Has a history of underlying pulmonary disorder including, but not limited to, pulmonary emboli within 3 months of the start of study treatment, severe asthma, severe COPD, restrictive lung disease, and other clinically significant pulmonary compromise or requirement for supplemental oxygen. 9. Clinically significant gastrointestinal disorder including, but not limited to, history of gastrointestinal fistulation that need long-term intravenous nutrition; gastrointestinal dysfunction that need long-term enteral nutrition through the tube feeding; gastrointestinal obstruction/perforation that not recovered within 6 months prior to the enrollment. 10. Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high risk of bleeding; A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment (Only applicable to HCC patients). 11. Metastatic disease that involves major airways or blood vessels (e.g., patients with vascular invasion of the major portal vein and inferior vena cava). 12. Clinically uncontrolled pleural effusion, ascites or pericardial effusion requiring drainage, peritoneal shunt or cell-free concentrated ascites reinfusion therapy within 2 weeks prior to the enrollment. 13. Any autoimmune, connective tissue or inflammatory disorders (e.g., rheumatoid arthritis, Sjögren's, sarcoidosis) where there is documented, or a suspicion of pulmonary involvement at the time of screening. 14. Has an uncontrolled infection requiring intravenous injection of antibiotics, antivirals, or antifungals. 15. Know human immunodeficiency virus (HIV) infection. 16. Subjects have active viral (any etiology) hepatitis are excluded. However, subjects with serologic evidence of chronic hepatitis B virus (HBV) infection (defined by a positive hepatitis B surface antigen \[HBsAg\] test or a positive hepatitis B core antibody test) who have a viral load below the limit quantification (e.g., HBV DNA titer \< 1000 cps/mL or 200 IU/mL) and are willing to and maintain antiviral treatment if required, are eligible. However, subjects with a history of hepatitis C virus (HCV) infection who have completed curative antiviral treatment and have a viral load below the limit of quantification are eligible for study entry. 17. Is a lactating mother (women who are willing to temporarily interrupt breastfeeding will also be excluded), or pregnant as confirmed by pregnancy tests performed within 7 days prior to enrollment. 18. Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. Subjects with clinically inactive brain metastases may be included in the study. Subjects with treated brain metastases that are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants may be included in the study if they have recovered from the acute toxic effect of radiotherapy. A minimum of 2 weeks must have elapsed between the end of whole brain radiotherapy and study randomization. 19. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI-CTCAE version 5.0, grade ≤ 1 or baseline. Subjects with chronic Grade 2 toxicities (e.g., Grade 2 neuropathy) may be eligible based on the discussion and agreement between Investigator and Sponsor. 20. Has multiple primary malignancies within 3 years before enrollment, except adequately resected non-melanoma skin cancer (e.g., resected basal or squamous cell skin cancer), curatively treated in-situ disease (e.g., carcinoma in situ of the cervix or breast), other solid tumors curatively treated (e.g., superficial bladder cancer), or contralateral breast cancer. 21. Has substance abuse or any other medical conditions that would increase the safety risk to the subject or interfere with participation or evaluation of the clinical study in the opinion of the investigator. 22. Has known hypersensitivity to either the drug substances or inactive ingredients in the drug product. 23. Patients with other reasons that, in the opinion of the Investigator, make them unsuitable to participate in this study. 24. Additional exclusion criteria for DDI cohort: Has a contraindication for receiving lopinavir, ritonavir or itraconazole according to the prescribing information is not able to take lopinavir, ritonavir or itraconazole by oral intake.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal squamous cell carcinoma hepatocellular carcinoma melanoma neoplasm non-small cell lung carcinoma prostate cancer small cell lung carcinoma Squamous Cell Carcinoma of Head and Neck Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced solid tumors

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

107 sites in 4 countries. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

Research Site 101
RECRUITING

Plantation, Florida, 33322, United States
Research Site 102
RECRUITING

Fairfax, Virginia, 22031, United States
Research Site 103
RECRUITING

Los Angeles, California, 90095, United States
Research Site 105
RECRUITING

Spokane, Washington, 99208, United States
Research Site 107
RECRUITING

New York, New York, 10032, United States
Research Site 108
RECRUITING

Greenville, South Carolina, 29607, United States
Research Site 109
RECRUITING

Tamarac, Florida, 33321, United States
Research Site 110
RECRUITING

Las Vegas, Nevada, 89169, United States
Research Site 111
RECRUITING

Tucson, Arizona, 85711, United States
Research Site 112
RECRUITING

Fairfax, Virginia, 22031, United States
Research Site 113
RECRUITING

Cincinnati, Ohio, 45267, United States
Research Site 114
RECRUITING

Atlanta, Georgia, 30318, United States
Research Site 115
RECRUITING

Louisville, Kentucky, 40202, United States
Research Site 118
RECRUITING

Celebration, Florida, 34747, United States
Research Site 120
RECRUITING

Dallas, Texas, 75390, United States
Research Site 121
RECRUITING

Saint Paul, Minnesota, 55101, United States
Research Site 123
RECRUITING

Charleston, South Carolina, 29425, United States
Research Site 125
RECRUITING

Los Angeles, California, 90033, United States
Research Site 127
RECRUITING

Margate, Florida, 33063, United States
Research Site 128
RECRUITING

Santa Monica, California, 90403, United States
Research Site 129
RECRUITING

Detroit, Michigan, 48201, United States
Research Site 131
RECRUITING

Dayton, Ohio, 45409, United States
Research Site 133
RECRUITING

Los Angeles, California, 90067, United States
Research Site 135
RECRUITING

Austin, Texas, 78731, United States
Research Site 136
RECRUITING

Nashville, Tennessee, 37203, United States
Research Site 137
RECRUITING

Orlando, Florida, 32827, United States
Research Site 138
RECRUITING

Canton, Ohio, 44718, United States
Research Site 139
RECRUITING

Atlanta, Georgia, 30322, United States
Research Site 201
RECRUITING

Sydney, New South Wales, 2031, Australia
Research Site 202
RECRUITING

Nedlands, Western Australia, 6009, Australia
Research Site 203
RECRUITING

Brisbane, Queensland, 4102, Australia
Research Site 205
RECRUITING

Sydney, New South Wales, 2109, Australia
Research Site 206
RECRUITING

Sydney, New South Wales, 2228, Australia
Research Site 207
RECRUITING

Nedlands, Western Australia, 6009, Australia
Research Site 208
RECRUITING

Blacktown, New South Wales, 2148, Australia
Research Site 209
RECRUITING

Birtinya, Queensland, 4575, Australia
Research Site 210
RECRUITING

Gold Coast, Queensland, 4224, Australia
Research Site 212
RECRUITING

Concord, New South Wales, 2139, Australia
Research Site 215
RECRUITING

Camperdown, New South Wales, 2050, Australia
Research Site 216
RECRUITING

Waratah, New South Wales, 2298, Australia
Research Site 217
RECRUITING

New Lambton Heights, New South Wales, 2305, Australia
Research Site 301
RECRUITING

Changchun, Jilin, 130012, China
Research Site 302
RECRUITING

Linyi, Shandong, 276034, China
Research Site 303
RECRUITING

Taizhou, Zhejiang, 317099, China
Research Site 304
RECRUITING

Zhengzhou, Henan, 450052, China
Research Site 305
RECRUITING

Nanjing, Jiangsu, 21000, China
Research Site 306
RECRUITING

Zhengzhou, Henan, 450000, China
Research Site 307
RECRUITING

Ganzhou, Jiangxi, 341000, China
Research Site 308
RECRUITING

Jinan, Shandong, 250117, China
Research Site 309
RECRUITING

Changsha, Hunan, 410031, China
Research Site 310
RECRUITING

Beijing, Beijing Municipality, 100142, China
Research Site 311
RECRUITING

Wuhan, Hubei, 430030, China
Research Site 312
RECRUITING

Chengdu, Sichuan, 610041, China
Research Site 313
RECRUITING

Fuzhou, Fujian, 350001, China
Research Site 314
RECRUITING

Guangzhou, Guangdong, 510060, China
Research Site 315
RECRUITING

Harbin, Heilongjiang, 150081, China
Research Site 316
RECRUITING

Luoyang, Henan, 450000, China
Research Site 317
RECRUITING

Xinxiang, Henan, 453100, China
Research Site 318
RECRUITING

Tianjin, Tianjin Municipality, 300060, China
Research Site 319
RECRUITING

Hefei, Anhui, 230031, China
Research Site 320
RECRUITING

Shenyang, Liaoning, 110000, China
Research Site 321
RECRUITING

Wuhan, Hubei, 430000, China
Research Site 322
RECRUITING

Guangzhou, Guangdong, 510060, China
Research Site 323
RECRUITING

Changsha, Hunan, 410031, China
Research Site 324
RECRUITING

Hangzhou, Zhejiang, 310014, China
Research Site 325
RECRUITING

Chengdu, Sichuan, 610072, China
Research Site 326
RECRUITING

Shanghai, Shanghai Municipality, 200032, China
Research Site 327
RECRUITING

Chongqing, Chongqing Municipality, 400030, China
Research Site 328
RECRUITING

Changchun, Jilin, 130000, China
Research Site 329
RECRUITING

Hangzhou, Zhejiang, 310016, China
Research Site 330
RECRUITING

Chengdu, Sichuan, 610041, China
Research Site 331
RECRUITING

Hangzhou, Zhejiang, 310022, China
Research Site 332
RECRUITING

Xi’an, Shanxi, 710000, China
Research Site 333
RECRUITING

Linyi, Shandong, 276000, China
Research Site 334
RECRUITING

Baoding, Hebei, 071030, China
Research Site 335
RECRUITING

Shanghai, Shanghai Municipality, 200030, China
Research Site 337
RECRUITING

Beijing, Beijing Municipality, 100142, China
Research Site 340
RECRUITING

Jinan, Shandong, 250013, China
Research Site 344
RECRUITING

Nanjing, Jiangsu, 210008, China
Research Site 345
RECRUITING

Chongqing, Chongqing Municipality, 400072, China
Research Site 346
RECRUITING

Guangzhou, Guangdong, 510282, China
Research Site 347
RECRUITING

Tianjin, Tianjin Municipality, 300052, China
Research Site 348
RECRUITING

Guangzhou, Guangdong, 510300, China
Research Site 349
RECRUITING

Nanchang, Jiangxi, 330006, China
Research Site 350
RECRUITING

Guangzhou, Guangdong, 510515, China
Research Site 352
RECRUITING

Shenyang, Liaoning, 110042, China
Research Site 353
RECRUITING

Chongqing, Chongqing Municipality, 400072, China
Research Site 355
RECRUITING

Shanghai, Shanghai Municipality, 200120, China
Research Site 356
RECRUITING

Chongqing, Chongqing Municipality, 400072, China
Research Site 359
RECRUITING

Hangzhou, Zhejiang, 310022, China
Research Site 360
RECRUITING

Nanning, Guangxi, 530021, China
Research Site 361
RECRUITING

Nanchang, Jiangxi, 330029, China
Research Site 363
RECRUITING

Nanjing, Nanjing, 210006, China
Research Site 365
RECRUITING

Beijing, Beijing Municipality, 100034, China
Research Site 366
RECRUITING

Chengdu, Sichuan, 610041, China
Research Site 401
RECRUITING

Taipei, 100225, Taiwan
Research Site 402
RECRUITING

Taipei, 100225, Taiwan
Research Site 403
RECRUITING

Taipei, 110301, Taiwan
Research Site 404
RECRUITING

Taoyuan, 333423, Taiwan
Research Site 405
RECRUITING

Kaohsiung City, 824005, Taiwan
Research Site 406
RECRUITING

New Taipei City, 235041, Taiwan
Research Site 407
RECRUITING

Taipei, 112201, Taiwan
Research Site 408
RECRUITING

Kaohsiung City, 807377, Taiwan
Research Site 409
RECRUITING

Taipei, 104217, Taiwan
Research site 367
RECRUITING

Guangzhou, Guangdong, 510120, China
Research site 368
RECRUITING

Tianjin, Tianjin Municipality, 300300, China
Research site 369
RECRUITING

Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.